Neurotoxin

Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease

Retrieved on: 
Monday, October 24, 2022
U.S. Securities and Exchange Commission, Therapy, SEC, Review, Amyloid-related imaging abnormalities, Neurotoxin, MAD, Private Securities Litigation Reform Act, ABOS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Patient, Research, Security (finance), Synapse, Collection, Food, Goal, Trial of the century, Neuron, Cell death, Mab, Pharmacokinetics, Safety, SAD, AD, Fast Track, GLOBE, FDA, NCT, Pathology, Neurodegeneration, ARIA, Pharmaceutical industry, Vaccine, Acumen

We are encouraged to receive Fast Track designation for ACU193, reflecting its potential clinical utility to treat Alzheimers disease, said Daniel OConnell, President and Chief Executive Officer of Acumen.

Key Points: 
  • We are encouraged to receive Fast Track designation for ACU193, reflecting its potential clinical utility to treat Alzheimers disease, said Daniel OConnell, President and Chief Executive Officer of Acumen.
  • We look forward to collaborating with the FDA to advance the development of ACU193.
  • The Fast Track designation allows Acumen to have more frequent engagement with the FDA to discuss development plans and clinical study design for ACU193 to ensure collection of appropriate data to support evaluation for approval.
  • Acumens scientific founders pioneered research on AOs, which a growing body of evidence indicates are primary triggers of Alzheimers disease pathology.

Orange County Research Institute Enrolling Patients in Anaheim for Clinical Trial of Promising New Investigational Treatment for Alzheimer’s Disease

Retrieved on: 
Monday, October 17, 2022
Health, General Health, Diabetes, Therapy, Risk, Diagnosis, Neurotoxin, Amyloid, Patient, Anaheim Regional Medical Center, Multimedia, MRI, Internal medicine, Osteoarthritis, Neuron, Mab, Amnesia, Safety, Protein, AD, Clinical trial, Brain, Peripheral neuropathy, PET, Suite, Neurodegeneration, Pharmaceutical industry, Medical imaging, Medical device, Hypertension, Hypercholesterolemia, Acumen, Fibromyalgia, Insomnia

Orange County Research Institute (OCRI) is initiating a clinical trial for a promising new investigational treatment for Alzheimers disease (AD) in Anaheim.

Key Points: 
  • Orange County Research Institute (OCRI) is initiating a clinical trial for a promising new investigational treatment for Alzheimers disease (AD) in Anaheim.
  • Acumen Pharmaceuticals Inc. , a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for AD, is sponsoring the clinical trial.
  • Were excited to open this trial in Anaheim to study ACU193 for the treatment of Alzheimers disease, Dr. Sitar said.
  • Orange County Research Institute is a clinical research center that has been serving the community since 2011.

SKINCEUTICALS SKINLAB™ ANNOUNCES LAUNCH OF SKINLUXE AND SKINCLEAR

Retrieved on: 
Monday, September 26, 2022
OXO-biodegradation, Blemish, Ageing, Twitter, Research, Program, Acne, Law firm network, Physician, SkinCeuticals, Light therapy, Rejuvenation, Dermatology, Neurotoxin, Silibinin, Cowra breakout, Vitamin, Massage, Overalls, Skin, Cosmetics, Facebook, Instagram

NEW YORK, Sept. 26, 2022 /PRNewswire/ -- SkinCeuticals, the #1 Medical Skincare Brand in the U.S.1, is expanding their range of signature treatments in SkinCeuticals SkinLab™ locations across the country with the additions of the SkinCeuticals SKINCLEAR, a targeted 30-minute treatment for acne-prone skin, and the SkinCeuticals SKINLUXE, a luxurious facial treatment targeting signs of aging. The two new services, adding to SkinCeuticals SkinLab™ targeted treatments addressing skin texture, brightness, and firmness, further the brand's mission of partnering with esteemed skincare professionals to provide professional-grade, approachable aesthetic services for every skin concern.

Key Points: 
  • NEW YORK, Sept. 26, 2022 /PRNewswire/ --SkinCeuticals, the #1 Medical Skincare Brand in the U.S.1, is expanding their range of signature treatments in SkinCeuticals SkinLab locations across the country with the additions of the SkinCeuticals SKINCLEAR, a targeted 30-minute treatment for acne-prone skin, and the SkinCeuticals SKINLUXE, a luxurious facial treatment targeting signs of aging.
  • SkinCeuticals SKINCLEAR is a targeted treatment to address the unique needs of acneic or combination skin.
  • The 60-minute SkinCeuticals SKINLUXE Signature Treatment is offered at the introductory price point of $225, and SkinCeuticals SKINCLEAR Signature Treatment for$150 at SkinCeuticals SkinLab locations nationwide near you (find yours at skinceuticals.com/skinlab).
  • SkinCeuticals is available in over 6,000 physician offices nationwide, with over 100 of those dermatologists and plastic surgeons exclusively selling SkinCeuticals through their flagship program and SkinCeuticals SkinLab destinations which specifically emphasize the SkinCeuticals integrated skincare approach combining clinical skincare with in-office treatments.

Hoag Enrolling Patients for Clinical Trial of Promising New Investigational Treatment for Alzheimer's Disease

Retrieved on: 
Tuesday, September 20, 2022
Therapy, Health, Neuroscience, Neurodegeneration, Safety, OC, Risk, Brain, AD, Amnesia, Elective surgery, News, Hoag, MRI, American Nurses Credentialing Center, Cognition, ANCC, Clinical trial, PET, Cancer, Physician, Protein, Mab, Neurotoxin, Diagnosis, AOS, Heart, Amyloid, Multimedia, Neuron, Asa, Medical imaging, Acumen, Alzheimer's disease

NEWPORT BEACH, Calif., Sept. 20, 2022 /PRNewswire/ -- Hoag's Pickup Family Neurosciences Institute is initiating a clinical trial for a promising new investigational treatment for Alzheimer's disease (AD).

Key Points: 
  • Acumen Pharmaceuticals Inc. , a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease, is sponsoring the clinical trial.
  • ACU193 targets amyloid-beta oligomers and is a different approach to treating Alzheimer's disease than currently approved medications.
  • These proteins are thought to be involved in Alzheimer's disease symptoms and progression.
  • "We're excited to open this trial at Hoag to study ACU193 for the treatment of Alzheimer's disease," said Gustavo Alva, M.D., DFAPA, a psychiatrist expert in cognition at Hoag and the principal investigator of the study.

Launch Of Aesthetic Medical Boutique Brand Profile MD Announced

Retrieved on: 
Monday, September 19, 2022
Health, Botulinum toxin, IV, Diet, MD, Plastic, Patient, Radio, Neurotoxin, Internal medicine, Preventive healthcare, Flex, Hyperhidrosis, Bariatrics, Pharmaceutical industry, Sculptra

SEVERNA PARK, Md., Sept. 19, 2022 /PRNewswire/ -- MD-based Profile MD has just announced the launch of their new aesthetic medical brand at 484A Ritchie Hwy, Severna Park, MD 21146.

Key Points: 
  • SEVERNA PARK, Md., Sept. 19, 2022 /PRNewswire/ -- MD-based Profile MD has just announced the launch of their new aesthetic medical brand at 484A Ritchie Hwy, Severna Park, MD 21146.
  • This new medical boutique will provide patients in the Maryland area with holistic care that encompasses aesthetic treatments, skin rejuvenation, medical weight loss, and more.
  • Profile MD will merge the procedures offered by the Laser Center of Maryland with an experienced team that supports its evolving mission.
  • The medical service clinicians will be expanding beyond medical aesthetics, non-invasive and minimally invasive procedures to prioritize wellness.

AMC Research Enrolling Patients near Charlotte, NC for Clinical Trial of Promising New Investigational Treatment for Alzheimer’s Disease

Retrieved on: 
Wednesday, September 7, 2022
Research, Mental Health, Seniors, Clinical Trials, Other Health, General Health, Pharmaceutical, Consumer, Health, Science, PET, AMC, Research, Dementia, Safety, Pseudodementia, Neuron, Brain, Protein, Mab, Amnesia, Collection, Vascular dementia, Diagnosis, Amyloid, Multimedia, Hospital, Frontotemporal dementia, MCI, Patient, Therapy, MRI, Neurotoxin, AD, Risk, Clinical trial, Neurodegeneration, Pharmaceutical industry, Medical imaging, Medical device, Parkinsonism, Acumen

AMC Research is initiating a clinical trial for a promising new investigational treatment for Alzheimers disease (AD) in Matthews, N.C.

Key Points: 
  • AMC Research is initiating a clinical trial for a promising new investigational treatment for Alzheimers disease (AD) in Matthews, N.C.
  • We are asking individuals who have memory problems to consider participating in the trial to assist in evaluating this medication for the treatment of Alzheimers disease.
  • Acumen Pharmaceuticals Inc. , a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for AD, is sponsoring the clinical trial.
  • Were excited to open this trial in Matthews to study ACU193 for the treatment of Alzheimers disease, Dr. Bolouri said.

Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights

Retrieved on: 
Monday, August 15, 2022
U.S. Securities and Exchange Commission, GLOBE, R, ABOS, SEC, Clinical trial, Board, Security (finance), Knowledge, Research, Marketing, Patient, Eli Lilly, SAD, G&A, Employment, NCT, Neuron, Cash balance plan, Safety, Neurodegeneration, Pathology, Conference, CMC, Pharmacokinetics, Forward-looking statement, MS, Poster, MAD, Eli Lilly and Company, Therapy, COVID-19, Program, PK, AD, Head, Goal, Neurotoxin, FDA, Private Securities Litigation Reform Act, Novavax, Mab, Goose egg addling, Research and development, Company, Fermentation, VP, NASDAQ, Neuroscience, Insurance, Administration, Pharmaceutical industry, Cryptocurrency, Vaccine, Chemistry, Acumen

We remain on track to report topline results in the first half of 2023, said Daniel OConnell, President and Chief Executive Officer of Acumen.

Key Points: 
  • We remain on track to report topline results in the first half of 2023, said Daniel OConnell, President and Chief Executive Officer of Acumen.
  • Acumen anticipates initiating a Phase 2/3 trial for ACU193 following completion of INTERCEPT-AD, if successful, and subsequent consultation and feedback from the FDA.
  • We thank Jeff for his service and support of Acumen over the last three years, said Dan OConnell, Chief Executive Officer of Acumen.
  • Acumen will host a conference call and live audio webcast today, August 15, 2022, at 4:30 pm ET.

Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®

Retrieved on: 
Tuesday, July 12, 2022
Other Health, Pharmaceutical, Luxury, Consumer, Cosmetics, Retail, Public Relations, Investor Relations, Clinical Trials, Women, Biotechnology, Communications, Health, Neurotoxin, SEC, Security (finance), Safety, Sale, U.S. Securities and Exchange Commission, Annual report, Development, LinkedIn, View, Patient, CEO, Phase, Instagram, COVID-19, Private Securities Litigation Reform Act, Population, Trial of the century, Nasdaq, Allergan, Forward-looking statement, FDA, Twitter, Efficiency, NASDAQ, Pharmaceutical industry, Kerosene, Facebook, Research

This study will help us to evaluate the safety, efficacy and the duration of effect of this increased dose.

Key Points: 
  • This study will help us to evaluate the safety, efficacy and the duration of effect of this increased dose.
  • The Extra-Strength Glabellar Line Study is a multicenter, double blind, randomized trial that is following 150 patients for up to 12 months at five study sites.
  • The study includes two active controls the currently approved 20 units of Jeuveau and 20 units of BOTOX Cosmetic which will be compared to 40 units of Jeuveau.
  • The safety and efficacy of Jeuveau was evaluated through the companys TRANSPARENCY program, the largest head-to-head pivotal study versus BOTOX to date.

Fastox to present its long-lasting botulinum toxin LAST™ technology at the TOXINS 2022 6th International Conference.

Retrieved on: 
Tuesday, July 5, 2022
Science, Toxin, Remora, Poster, Technology, University, Doctor of Philosophy, Neurotoxin, Toxicon, Bont, International Conference on Advances in ICT for Emerging Regions, Conference, Pharmaceutical industry

Fastox to present its long-lasting botulinum toxin LAST technology at the TOXINS 2022 6th International Conference.

Key Points: 
  • Fastox to present its long-lasting botulinum toxin LAST technology at the TOXINS 2022 6th International Conference.
  • Lausanne, July 5th, 2022 Swiss biotech Fastox Pharma will present for the first time its groundbreaking long-lasting botulinum toxin LAST technology at the leading conference on neurotoxins from July 27th to July 30th in New Orleans, USA.
  • Fastox VP Innovation, Mickal Machicoane, PhD, says: I am honored to present our discovery at the Toxins 2022 International Conference towards renowned experts from all over the globe.
  • Fastox proprietary LAST (Long-Acting Strengthened Toxin) technology allows to boost the performance of botulinum toxins A by combining them with safe myorelaxant drugs.

Resilience Announces $625 Million Series D Financing to Expand Network, Bring Innovative Technologies to Biomanufacturing

Retrieved on: 
Monday, June 6, 2022
Biotechnology, Pharmaceutical, Other Manufacturing, Health, Technology, Genetics, Manufacturing, Other Technology, Opus, Science, LinkedIn, Organic acid, Organization, Retina, U.S. Department of Defense Strategy for Operating in Cyberspace, Defense, Harvard University, Government, Vaccine, Growth, Neurotoxin, Patient, Technology, Research Triangle, Research, Social media, Industry, Drug discovery, University, MD Anderson Cancer Center, Cancer, CHOP, Fine chemical, Pharmaceutical industry, Medical device, Resilience

National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced it has raised $625 million in a Series D financing, in addition to a previously unannounced $600 million Series C financing completed in August 2021.

Key Points: 
  • National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced it has raised $625 million in a Series D financing, in addition to a previously unannounced $600 million Series C financing completed in August 2021.
  • While we recognize that our goal is neither quick nor easy, we are driven by our mission to democratize access to medicines.
  • In total, Resilience has secured more than $2 billion in equity financing since its founding in 2020.
  • For more information, visit www.Resilience.com and follow us on social media: @IncResilience on Twitter and Resilience on LinkedIn.